Aristotle Capital Boston LLC Reduces Holdings in Prestige Consumer Healthcare Inc. $PBH

Posted by Stanley Muller on Jun 18th, 2026

Aristotle Capital Boston LLC lowered its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 294,932 shares of the company’s stock after selling 30,873 shares during the period. Aristotle Capital Boston LLC’s holdings in Prestige Consumer Healthcare were worth $18,194,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA increased its stake in shares of Prestige Consumer Healthcare by 10.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock worth $40,147,000 after buying an additional 60,496 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Prestige Consumer Healthcare by 547.4% in the fourth quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock worth $37,811,000 after buying an additional 520,186 shares during the last quarter. Leeward Investments LLC MA increased its stake in shares of Prestige Consumer Healthcare by 23.3% in the fourth quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock worth $23,894,000 after buying an additional 73,162 shares during the last quarter. Legato Capital Management LLC increased its stake in shares of Prestige Consumer Healthcare by 532.4% in the fourth quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock worth $1,713,000 after buying an additional 23,382 shares during the last quarter. Finally, Brandes Investment Partners LP increased its stake in shares of Prestige Consumer Healthcare by 93.2% in the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after buying an additional 292,744 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares of the company’s stock, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PBH. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Finally, Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $70.75.

Check Out Our Latest Stock Analysis on Prestige Consumer Healthcare

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $45.99 on Thursday. The company has a market cap of $2.18 billion, a PE ratio of 11.76, a P/E/G ratio of 1.53 and a beta of 0.35. The company has a fifty day moving average price of $51.60 and a two-hundred day moving average price of $59.33. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $85.29.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Prestige Consumer Healthcare Profile

(Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).